Musculoskeletal system

Seminars in Nuclear Medicine

Volumn 34, Issue 4, 2004, Pages 254-261

  Jadvar, Hossein ^a   Gamie, Sherief ^a   Ramanna, Lalitha ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE MEGLUMINE; IMATINIB; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

BONE METASTASIS; BONE SCINTISCANNING; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHONDROSARCOMA; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG UPTAKE; EWING SARCOMA; FIBROSARCOMA; FIBROUS DYSPLASIA; GASTROINTESTINAL STROMAL TUMOR; GIANT CELL TUMOR; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG METASTASIS; MALIGNANT FIBROUS HISTIOCYTOMA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PAGET BONE DISEASE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; SOFT TISSUE TUMOR;

EID: 5444233681     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2004.06.002     Document Type: Article

References (74)

1. National Cancer Institute Surveillance, Epidemiology, and End Results (NCI-SEER) Program http://seer.cancer.gov 2003
2. P.S. Conti, D.L. Lilien, S.T. Grafton PET and [18F]-FDG A clinical update Nucl Med Biol 23 1996 717 735
3. R.J. Hicks Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas Acta Orthop Scand Suppl 273 1997 25 36
4. D.G. Varma Imaging of soft-tissue sarcomas Curr Oncol Rep 2 2000 487 490
5. H.J. Mankin, C.G. Willett, D.C. Harmon Malignant tumors of bone A.I. Holleb D.J. Fink G.P. Murphy Clinical Oncology 1991 American Cancer Society Atlanta, GA 355 358
6. D. Jaramillo, T. Laor, M. Gebhardt Pediatric musculoskeletal neoplasms. Evaluation with MR imaging MRI Clin North Am 4 1996 1 22
7. R. Erlemann, J. Sciuk, A. Bosse Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy Assessment with dynamic and static MR imaging and skeletal scintigraphy Radiology 175 1990 791 796
8. H.C. Holscher, J.L. Bloem, D. Vanel Osteosarcoma Chemotherapy-induced changes at MR imaging Radiology 182 1992 839 844
9. L. Ramanna, A. Waxman, G. Binney Thallium-201 scintigraphy in bone sarcoma Comparison with gallium-67 and technetium-99m MDP in the evaluation of chemotherapeutic response J Nucl Med 31 1990 567 572
10. L.R. Menendez, B.M. Fideler, J. Mirra Thallium-201 scanning for the evaluation of osteosarcoma and soft tissue sarcoma J Bone Joint Surg 75 1993 526 531
11. L. Kostakoglu, D.M. Panicek, C.R. Divgi Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas Eur J Nucl Med 22 1995 1232 1237
12. H.M. Abdel-Dayem The role of nuclear medicine in primary bone and soft tissue tumors Semin Nucl Med 27 1997 355 363
13. B. Caner, M. Kitapel, M. Unlu Technetium-99m-MIBI uptake in benign and malignant bone lesions a comparative study with technetium-99m-MDP J Nucl Med 33 1992 319 324
14. R. Garcia, E.E. Kim, F.C. Wong Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas J Nucl Med 37 1996 1476 1479
15. J. Aoki, T. Inoue, K. Tomiyoshi Nuclear imaging of bone tumors FDG-PET Semin Musculoskelet Radiol 5 2001 183 187
16. W. Brenner, K.H. Bohuslavizki, J.F. Eary PET imaging of osteosarcoma J Nucl Med 44 2003 930 942
17. M. Schulte, D. Brecht-Krauss, B. Heymer Fluorodeoxyglucose positron emission tomography of soft tissue tumours Is a non-invasive determination of biological activity possible? Eur J Nucl Med 26 1999 599 605
18. J. Aoki, H. Watanabe, T. Shinozaki FDG PET of primary benign and malignant bone tumors standardized uptake value in 52 lesions Radiology 219 2001 774 777
19. A.L. Folpe, R.H. Lyles, J.T. Sprouse (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma Clin Cancer Res 6 2000 1279 1287
20. S.F. Hain, M.J. O'Doherty, J.D. Lucas Fluorodeoxyglucose PET in the evaluation of amputations for soft tissue sarcoma Nucl Med Commun 20 1999 845 848
21. N. Tse, C. Hoh, R. Hawkins Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma Am J Clin Oncol 17 1994 22 25
22. C. Franzius, H.E. Daldrup-Link, J. Sciuk FDG-PET for detection of pulmonary metastases from malignant primary bone tumors comparison with spiral CT Ann Oncol 12 2001 479 486
23. C. Franzius, J. Sciuk, H.E. Daldrup-Link FDG-PET for detection of osseous metastases from malignant primary bone tumors comparison with bone scintigraphy Eur J Nucl Med 27 2000 1305 1311
24. M. Schulte, D. Brecht-Krauss, M. Werner Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET J Nucl Med 40 1999 1637 1643
25. C. Franzius, J. Sciuk, C. Brinkschmidt Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis Clin Nucl Med 25 2000 874 881
26. N. Nair, A. Ali, A.A. Green Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET scans Clin Positron Imaging 3 2000 79 83
27. D.S. Hawkins, J.G. Rajendran, E.U. Conrad 3rd Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography Cancer 94 2002 3277 3284
28. C. Franzius, S. Bielack, S. Flege Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma J Nucl Med 43 2002 1012 1017
29. R.L. Page, P.K. Garg, S. Garg PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment J Nucl Med 35 1994 1506 1513
30. C.K. Hoh, R.A. Hawkins, M. Dahlbom Whole body skeletal imaging with [18F]fluoride ion and PET J Comput Assist Tomogr 17 1993 34 41
31. M.C. Posner, M.F. Brennan Soft tissue sarcomas A.I. Holleb D.J. Fink G.P. Murphy Clinical Oncology 1991 American Cancer Society Atlanta, GA 359 376
32. K.A. Kern, A. Brunetti, J.A. Norton Metabolic imaging of human extremity musculoskeletal tumors by PET J Nucl Med 29 1988 181 186
33. D.A. Podoloff The role of radionuclide scans in sarcoma Hematol Oncol Clin North Am 9 1995 605 626
34. F. Miraldi, L.P. Adler, P. Faulhaber PET imaging in soft tissue sarcomas Cancer Treat Res 91 1997 51 64
35. J.F. Eary, E.U. Conrad, J.D. Bruckner Quantitative [F-18] fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma Clin Cancer Res 4 1998 1215 1220
36. H. Watanabe, T. Shinozaki, T. Yanagawa Glucose metabolic analysis of musculoskeletal tumors using 18fluorine-FDG PET as an aid to preoperative planning J Bone Joint Surg Br 82 2000 760 767
37. N. Israel-Mardirosian, L.P. Adler Positron emission tomography of soft tissue sarcomas Curr Opin Oncol 15 2003 327 330
38. F. Feldman, R. van Heertum, C. Manos 18FDG PET scanning of benign and malignant musculoskeletal lesions Skeletal Radiol 32 2003 201 208
39. L.P. Adler, H.F. Blair, R.P. Williams Grading liposarcomas with PET using [18F]FDG J Comput Assist Tomogr 14 1990 960 962
40. S. Kosuda, R.L. Wahl, H.B. Grossman Demonstration of recurrent dedifferentiated liposarcoma of the spermatic cord by FDG-PET Ann Nucl Med 11 1997 263 266
41. J. Aoki, H. Watanabe, T. Shinozaki FDG-PET in differential diagnosis and grading of chondrosarcomas J Comput Assist Tomogr 23 1999 603 608
42. R.L. Thurer, A. Thorsen, J.A. Parker FDG imaging of a pulmonary artery sarcoma Ann Thorac Surg 70 2000 1414 1415
43. H. Jadvar, A.J. Fischman Evaluation of rare tumors with [F-18]-fluorodeoxyglucose positron emission tomography Clin Positron Imaging 2 1999 153 158
44. J. Aoki, K. Endo, H. Watanabe FDG-PET for evaluating musculoskeletal tumors A review J Orthop Sci 8 2003 435 441
45. B. Hegner, B. Krakamp, J.P. Hedde Positron emission tomography reveals a leiomyosarcoma causing proteinuria Clin Nephrol 60 2003 139 142
46. J.H. Kim, F.R. Gutierrez, E.Y. Lee Primary leiomyosarcoma of the pulmonary artery a diagnostic dilemma Clin Imaging 27 2003 206 211
47. M.W. Ben Arush, O. Israel, Z. Kedar Detection of isolated distant metastasis in soft tissue sarcoma by fluorodeoxyglucose positron emission tomography case report Pediatr Hematol Oncol 18 2001 295 298
48. M.H. Schwarzbach, A. Dimitrakopoulou-Strauss, G. Mechtersheimer Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET) Anticancer Res 21 2001 3609 3614
49. S. Stroobants, J. Goeminne, M. Seegers 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 2003 2012 2020
50. L.S. Freudenberg, S.J. Rosenbaum, J. Schulte-Herbruggen Diagnosis of a cardiac angiosarcoma by fluorine-18 fluordeoxyglucose positron emission tomography Eur Radiol 12 suppl 3 2002 S158 S161
51. S.F. Hain, M.J. O'Doherty, J. Bingham Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumors? Nucl Med Commun 24 2003 1139 1143
52. J.D. Lucas, M.J. O'Doherty, B.F. Cronin Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography Br J Surg 86 1999 550 556
53. J.D. Lucas, M.J. O'Doherty, J.C. Wong Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas J Bone Joint Surg Br 80 1998 441 447
54. E. Bastiaannet, H. Groen, P.L. Jager The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; A systematic review and meta-analysis Cancer Treat Rev 30 2004 83 101
55. J.P. Ioannidis, J. Lau 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma A meta-analysis J Nucl Med 44 2003 717 724
56. M.H. Schwarzbach, A. Dimitrakopoulou-Strauss, F. Willeke Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas Ann Surg 231 2000 380 386
57. O.E. Nieweg, J. Pruim, R.J. van Ginkel Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma J Nucl Med 37 1996 257 261
58. J.F. Eary, D.A. Mankoff Tumor metabolic rates in sarcoma using FDG PET J Nucl Med 39 1998 250 254
59. A. Dimitrakopoulou-Strauss, L.G. Strauss, M. Schwarzbach Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas impact on diagnosis and correlation with grading J Nucl Med 42 2001 713 720
60. M.A. Lodge, J.D. Lucas, P.K. Marsden A PET study of 18FDG uptake in soft tissue masses Eur J Nucl Med 26 1999 22 30
61. R.J. van Ginkel, H.J. Hoekstra, J. Pruim FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma J Nucl Med 37 1996 984 990
62. P.S. Conti, L.R. Menedez, L. Ramanna Use of positron emission tomography in the evaluation of cryosurgical treatment of musculoskeletal tumors Radiology 213 1999 118
63. C.B. Vernon, J.F. Eary, B.P. Rubin FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma Skeletal Radiol 32 2003 139 142
64. A.D. Van den Abbeele, R.D. Badawi Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs) Eur J Cancer 38 suppl 5 2002 S60 S65
65. G. Antoch, J. Kanja, S. Bauer Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors J Nucl Med 45 2004 357 365
66. I. Gayed, T. Vu, R. Iyer The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors J Nucl Med 45 2004 17 21
67. M.A. Bredella, G.R. Caputo, L.S. Steinbach Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas Am J Roentgenol 179 2002 1145 1150
68. D.N. Jones, G.B. McCowage, H.D. Sostman Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET J Nucl Med 37 1996 1438 1444
69. A.C. Kole, O.E. Nieweg, R.J. van Ginkel Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F] fluorodeoxyglucose Ann Surg Oncol 4 1997 57 63
70. H. el-Zeftawy, S.I. Heiba, S. Jana Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma Cancer Biother Radiopharm 16 2001 37 46
71. J.F. Eary, F. O'Sullivan, Y. Powitan Sarcoma tumor FDG uptake measured by PET and patient outcome A retrospective analysis Eur J Nucl Med Mol Imaging 29 2002 1149 1154
72. T. Yanagawa, H. Watanabe, T. Inoue Carbon-11 choline positron emission tomography in musculoskeletal tumors Comparison with fluorine-18 fluorodeoxyglucose positron emission tomography J Comput Assist Tomogr 27 2003 175 182
73. M. Schwarzbach, F. Willeke, A. Dimitrakopoulou-Strauss Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography Anticancer Res 19 1999 1343 1349
74. C. Franzius, M. Schulte, A. Hillmann Clinical value of positron emission tomography (PET) in the diagnosis of bone and soft tissue tumors. 3rd Interdisciplinary Consensus Conference "PET in Oncology": Results of the Bone and Soft Tissue Study Group Chirurg 72 2001 1071 1077